Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H2 2016, provides an overview of the Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline landscape. Polyarticular juvenile idiopathic arthritis (PJIA) affects five or more joints. PJIA causes inflammation in small joints of the fingers and hands, but weight-bearing joints and the jaw can also be affected. Symptoms include fevers, pink rash, eye inflammation, joint pain, joint swelling and problems with bone development and growth. Treatment includes painkillers, NSAID and disease-modifying anti-rheumatic drugs. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 1, 2, 9, 1 and 1 respectively.Polyarticular Juvenile Idiopathic Arthritis (PJIA). Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders). - The pipeline guide reviews pipeline therapeutics for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Polyarticular Juvenile Idiopathic Arthritis (PJIA) Overview 7 Therapeutics Development 8 Pipeline Products for Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Overview 8 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics under Development by Companies 9 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Unknown Stage Products 13 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Products under Development by Companies 14 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Companies Involved in Therapeutics Development 15 Biocon Ltd 15 Coherus BioSciences Inc 16 Livzon Pharmaceutical Group Inc 17 Marathon Pharmaceuticals LLC 18 Momenta Pharmaceuticals Inc 19 Mycenax Biotech Inc 20 NeuClone Pty Ltd 21 Oncobiologics Inc 22 Oncodesign SA 23 Panacea Biotec Ltd 24 Regeneron Pharmaceuticals Inc 25 Sandoz International GmbH 26 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 abatacept biosimilar - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 adalimumab biosimilar - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 adalimumab biosimilar - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 adalimumab biosimilar - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 adalimumab biosimilar - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 adalimumab biosimilar - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 adalimumab biosimilar - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 deflazacort - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 etanercept biosimilar - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 etanercept biosimilar - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 etanercept biosimilar - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 etanercept biosimilar - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 etanercept biosimilar - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 methotrexate - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 sarilumab - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Small Molecules to Inhibit RIP2 for Polyarthritis, Gastrointestinal Disorders and Rheumatoid Arthritis - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 tocilizumab biosimilar - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 tocilizumab biosimilar - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 tocilizumab biosimilar - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects 65 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Product Development Milestones 66 Featured News & Press Releases 66 Nov 02, 2016: Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA (abatacept) 66 Aug 30, 2016: FDA approves Erelzi, a biosimilar to Enbrel 66 Jul 13, 2016: Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases 67 Appendix 69 Methodology 69 Coverage 69 Secondary Research 69 Primary Research 69 Expert Panel Validation 69 Contact Us 69 Disclaimer 70
List of Tables
Number of Products under Development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Comparative Analysis by Unknown Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Biocon Ltd, H2 2016 15 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Coherus BioSciences Inc, H2 2016 16 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Livzon Pharmaceutical Group Inc, H2 2016 17 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Marathon Pharmaceuticals LLC, H2 2016 18 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Momenta Pharmaceuticals Inc, H2 2016 19 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Mycenax Biotech Inc, H2 2016 20 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by NeuClone Pty Ltd, H2 2016 21 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Oncobiologics Inc, H2 2016 22 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Oncodesign SA, H2 2016 23 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Panacea Biotec Ltd, H2 2016 24 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 25 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Sandoz International GmbH, H2 2016 26 Assessment by Monotherapy Products, H2 2016 27 Number of Products by Stage and Target, H2 2016 29 Number of Products by Stage and Mechanism of Action, H2 2016 31 Number of Products by Stage and Route of Administration, H2 2016 33 Number of Products by Stage and Molecule Type, H2 2016 35 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects, H2 2016 65
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
